Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | GPR174 | Q9BXC1 | 4/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31157984 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MAPTLMNAGPR174GPR119 | |
| SCHEMBL31157987 | 0.88 | ALDH1A1 (0.65) | ALDH1A1MAPTLMNAGPR174CYP1A2 | |
| SCHEMBL23293433 | 0.88 | ALDH1A1 (0.65) | ALDH1A1MAPTLMNAGPR174CYP1A2 | |
| SCHEMBL27691387 | 0.86 | MAPT (0.56) | ALDH1A1MAPTLMNAGPR174CYP1A2 | |
| SCHEMBL31000429 | 0.85 | ALDH1A1 (0.64) | ALDH1A1MAPTLMNACYP1A2CYP2C19 | |
| SCHEMBL16270620 | 0.84 | MAPT (0.71) | ALDH1A1MAPTLMNAGPR119CYP1A2 | |
| SCHEMBL29858317 | 0.84 | MAPT (0.71) | ALDH1A1MAPTLMNAGPR119CYP1A2 | |
| SCHEMBL3536583 | 0.84 | ALDH1A1 (0.61) | ALDH1A1MAPTLMNAGPR119CYP1A2 | |
| SCHEMBL30412714 | 0.83 | MAPT (0.63) | ALDH1A1MAPTLMNAGPR119CYP1A2 | |
| SCHEMBL25198798 | 0.83 | MAPT (0.63) | ALDH1A1MAPTLMNAGPR119CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024163382-A2 | 18F-LABELED PET RADIOTRACERS FOR IMAGING MACROPHAGE COLONY STIMULATING FACTOR 1 RECEPTOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-08-08 | — | — | WO | disclosed |
| US-20210290784-A1 | POSITRON EMISSION TOMOGRAPHY (PET) RADIOTRACERS FOR IMAGING MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) IN NEUROINFLAMMATION | THE JOHNS HOPKINS UNIVERSITY | 2021-09-23 | — | — | US | disclosed |
| EP-3813890-A1 | POSITRON EMISSION TOMOGRAPHY (PET) RADIOTRACERS FOR IMAGING MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) IN NEUROINFLAMMATION | The Johns Hopkins University (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-112638431-A | Positron Emission Tomography (PET) radiotracers for imaging macrophage colony stimulating factor 1 receptor (CSF1R) in neuroinflammation | 约翰霍普金斯大学 | 2021-04-09 | — | — | CN | disclosed |
| US-7705042-B2 | Class of arylamide compounds useful as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7705042-B2 | Class of arylamide compounds useful as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7705042-B2 | Class of arylamide compounds useful as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-27 | — | — | US | disclosed |
| EP-1807407-B1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-29 | — | — | EP | disclosed |
| EP-1807407-B1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-29 | — | — | EP | disclosed |
| EP-1807407-A1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | disclosed |
| US-20060100201-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | US | disclosed |
| WO-2006047504-A1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100201-A1 | Inhibitors of c-fms kinase | MUSK, FLT3, FES | ALDH1A1 4796/4885MAPT 159/4885LMNA 3053/4885 |
| US-20210290784-A1 | POSITRON EMISSION TOMOGRAPHY (PET) RADIOTRACERS FOR IMAGING MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) IN NEUROINFLAMMATION | CSF1R, CSF3R, CMKLR1 | ALDH1A1 2911/4885MAPT 187/4885LMNA 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.